A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2015
Price : $35 *
At a glance
- Drugs Andecaliximab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 14 Sep 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.